EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2024-09
• Main Authors: An, Zhenyi, Fan, Qi-Wen, Wang, Linyu, Yoda, Hiroyuki, Barata, Megumi J, Jimenez-Morales, David, Phillips, Joanna J, Swaney, Danielle L, Stevenson, Erica, Lee, Ethan, Krogan, Nevan, Weiss, William A
• Format: Article
• Language: English
• ISSN: 1522-8517; 1523-5866; 1523-5866
• DOI: 10.1093/neuonc/noae182

Co-amplification of EGFR and EGFRvIII, a tumor-specific truncation mutant of EGFR, represent hallmark genetic lesions in glioblastoma. We used phospho-proteomics, RNA-sequencing, TCGA data and glioblastoma cell culture and mouse models to study the signal transduction mediated by EGFR and EGFRvIII. We report that EGFR and EGFRvIII stimulate the innate immune defense receptor Toll-like Receptor 2 (TLR2); and that knockout of TLR2 dramatically improved survival in orthotopic glioblastoma xenografts. EGFR and EGFRvIII activated TLR2 in a ligand-independent manner, promoting tumor growth and immune evasion. We show that EGFR and EGFRvIII cooperate to activate the Rho-associated protein kinase ROCK2, which modulated malignant progression both by activating TLR2 and WNT signaling, and through remodeling the tumor microenvironment. Together, our findings show that EGFR and EGFRvIII cooperate to drive tumor progression through ROCK2 and downstream WNT-β-catenin/TLR2 signaling pathways.